Evidence map›Paper›PMID 40969753›Full record

ArticleFrontiers in immunology2025

Gut mycobiota dysbiosis and systemic immune dysfunction in Chinese schizophrenia patients with metabolic syndrome.

Zongxin Ling, Yiwen Cheng, Zhiyong Lan, Xia Liu, Zhangcheng Zhu, Wenwen Ding, Xiaocui Xu, Pian Yu, Xiaoxun Xu, Li Shao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zongxin Ling *State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yiwen Cheng *State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, China-Singapore Belt and Road Joint Laboratory on Infection Research and Drug Development, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhiyong Lan *Department of Psychiatry, Quzhou Third Hospital, Quzhou, Zhejiang, China.
Xia Liu *Department of Intensive Care Unit, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Zhangcheng ZhuDepartment of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wenwen DingDepartment of Anesthesiology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Xiaocui XuDepartment of Anesthesiology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Pian YuDepartment of Psychiatry, Quzhou Third Hospital, Quzhou, Zhejiang, China.
Xiaoxun XuDepartment of Psychiatry, Quzhou Third Hospital, Quzhou, Zhejiang, China.
Li ShaoSchool of Clinical Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China.
Qinghai SongDepartment of Psychiatry, Lishui Second People's Hospital, Lishui, Zhejiang, China.
Rongxian LiaoDepartment of Psychiatry, Quzhou Third Hospital, Quzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While bacterial dysbiosis has been extensively studied in schizophrenia with metabolic syndrome (SZ-MetS), the role of gut mycobiota in this comorbidity remains unclear. This study represents the first comprehensive investigation of fungal communities in SZ-MetS patients (n=109) versus healthy controls (HCs, n=101) using ITS1 sequencing and multi-parameter immune profiling. Although global mycobiota structure showed no significant differences, compositional analyses revealed profound taxonomic shifts: pathobionts (

Indexed as

DysbiosisFungiGastrointestinal MicrobiomeMetabolic SyndromeMycobiomeSchizophreniaAdultChinaEast Asian PeopleFemaleHumansMaleMiddle Agedgut-brain axisimmunological dysfunctionmetabolic syndromemycobiotaschizophrenia

Identifiers

PMID40969753
PMCPMC12440738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.